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Mitochondrial cytochrome c (cyt. c) release and caspase activation are often impaired in tumors with Bcl-2 overexpression or
Bax and Bak-defective status. Direct triggering of cell death downstream of Bax and Bak is an attractive strategy to kill such
cancers. Small molecule compounds capable of direct caspase activation appear to be the best mode for killing such tumors.
However, there is no precise model to screen such compounds. The currently employed cell-free systems possess the inherent
drawback of lacking cellular contents and organelles that operate in integrating cell death signaling. We have developed highly
reﬁned cell-based approaches to validate direct caspase activation in cancer cells. Using this approach, we show that PAC-1
(ﬁrst procaspase-activating compound), the ﬁrst direct activator of procaspases identiﬁed in a cell-free system, in fact requires
mitochondrial cyt. c release for triggering caspase activation similar to other antitumor agents. It can induce signiﬁcant caspase
activationandcelldeathintheabsenceofBaxandBak,andincellsoverexpressingBcl-2andBcl-xL.Thisstudyfortheﬁrsttime
deﬁnes precise criteria for the validation of direct caspase-activating compounds using specialized cellular models that is
expected to accelerate the discovery of potential direct caspase activators.
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Caspase activation essentially requires cytochrome c (cyt. c),
Apaf-1 and procaspase-9 to be recruited in the apoptosome
complex in the cytosol, thereby necessitating the release of
cyt. c from mitochondria as a crucial event of programmed
cell death.
1,2 So, caspase activation is initiated only after
Bax and Bak-dependent cyt. c release, a process that is
often inhibitable by antiapoptotic Bcl-2 family proteins.
3
Aberrant expression of Bcl-2 family proteins correlate well
with prognosis and treatment outcome, and often contributes
for drug failure in cancer chemotherapy.
4 Hypothetically,
direct targeting of downstream proteins of the apoptotic
cascade by therapeutic agents will be an ideal and successful
strategy in killing such resistant tumors. Direct caspase
activators, especially that of executioner caspase-3 have
received signiﬁcant attention because such compounds
would be ideal in killing cancers with aberrant pro- and
antiapoptotic protein expression.
5 Recently two independent
research groups identiﬁed several direct caspase activators
using cell-free assay systems.
6,7 The ﬁrst procaspase-
activating compound (PAC-1) shown to activate procas-
pase-3 to caspase-3 by sequestering inhibitory zinc ions,
created signiﬁcant interest in the scientiﬁc community
because of its potential to form the basis of new anti-
neoplastic therapeutics.
8,9
Even though cell-free system of caspase activation is ideal
to identify lead molecules from large compound libraries, it is
doubtful that such hits, which convert recombinant procas-
pase-3 to caspase-3 in deﬁned buffer system, can indeed
generate active caspase-3 in cells where multiple proteins
and organelles contribute for caspase activation. Considering
the tremendous potential of such compounds in addressing
clinical drug resistance, it is important to deﬁne the minimum
molecular signatures in deﬁned cell models to pick up
direct caspase activators from classical caspase-activating
compounds. Indeed, it is a challenge to deﬁne the border
line between direct and indirect caspase activation, consider-
ing the complex network of signaling that often proceeds
rapidly, once initiated, with multiple complex feedback
mechanisms.
10,11
Considering the dominant role of cyt. c in the initiation of
caspase activation, by theory, if direct caspase-3 activation
is possible, caspase activity can be detected well before cyt. c
release or without its release.
12 In order to deﬁne direct
caspase activation, we employed live cell-based systems to
evaluate cyt. c release, mitochondrial outer membrane
permeabilization and caspase activation in real time and
hierarchical manner.
13 Our study using such tools suggests
that PAC-1 requires cyt. c release from mitochondria, and
Apaf-1 for caspase-3 activation. However, PAC-1 is a
potential drug to bypass the Bcl-2/Bcl-xL resistance and is
capable to induce Bax and Bak-independent cell death
effectively. The cellular model described here can form an
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ing compounds, as well as in deﬁning the minimum criteria
for distinguishing direct caspase activators from classical
apoptosis inducing compounds.
Results
Tracking of cyt. c release in real time. Apoptosome
complex assembly and activation of procaspase-9, is
initiated in the cytosol only after the release of cyt. c from
mitochondria to cytosol.
2 Theoretically, if direct caspase
activation is possible, it would generate cytosolic active
caspase well before cyt. c release. Therefore, the primary
goal was to develop cellular models to deﬁne direct caspase
activation from classical apoptosis by kinetic evaluation of
cyt. c release and caspase activation systematically in live
cells. We generated several cancer cell lines expressing cyt. c
stably with enhanced green ﬂuorescent protein (EGFP)
fusion. The correct targeting and its potential to release
upon apoptosis were evaluated by imaging using multiple
drugs. The representative images of SiHa cyt. c-EGFP stable
cells expressing mitochondrial-targeted DsRed and its
response with different drugs is shown (Supplementary
Figure S1a). Employing these cellular models, we
evaluated cyt. c release by the ﬁrst reported procaspase-3
activating small molecule, PAC-1. It induced signiﬁcant cyt. c
release in SW480 and SiHa cells, and none of the cells under
study showed evidence of cell death without cyt. c release
(Supplementary Figures S1b and c).
For tracking cyt. c release and its dependency on caspase-3
in a real time manner, we carried out live-cell imaging in
endogenous caspase-3-expressing SW480, caspase-3-
deﬁcient MCF7 and caspase-3-expressing MCF7(MCFC3)
cells (Supplementary Videos S1, S2 and S3; Figures 1a–c).
Time-lapseimagingsuggestedthatcyt.creleasewasinitiated
before 6h in SW480 cells upon PAC-1 treatment. Surpris-
ingly, in MCF7 and MCFC3 cells, cyt. c release was initiated
almost at the same time, that is, around 8–9h after PAC-1
treatment. Remarkably, MCFC3 cells underwent rapid cell
death than MCF7 cells after cyt. c release, as evident from the
morphological changes and nuclei condensation. Immunoblot
also substantiated the cyt. c release kinetics to be consistent
with imaging data (Figures 1a–c). The results indicate that
PAC-1 induces cyt. c release in a caspase-3 independent
manner but in the presence of caspase-3, cells undergo rapid
death after cyt. c release consistent with its potential ability to
acceleratecelldeath.Furthermore,weanalyzedcyt.crelease
in MCFC3 cyt. c-EGFP cells using various concentration of
PAC-1, which substantiated that cyt. c release was delayed
signiﬁcantly below 30mM of PAC-1 concentration (Supple-
mentary Figure S2a and b).
Tracking of caspase activation in real time. The integra-
tion of cyt. c release kinetics with temporal information of
caspase activation in the same cells is a prerequisite to rule
out the cyt. c-dependent or -independent pattern of caspase
activation. As the time gap between cyt. c release and
caspase activation is known to vary signiﬁcantly between
cells, it is quite possible that rare events are likely to be
missed in end-point assays. This necessitates the need for a
live cell-based approach to monitor caspase activation in real
time. We have employed a ﬂuorescence resonance energy
transfer (FRET) probe-based caspase activation sensor
consisting of donor ECFP and acceptor enhanced yellow
ﬂuorescent protein (EYFP) ﬂuorophores linked to caspase-3,
7 speciﬁc amino-acid linker DEVD (Figure 2a) as
described.
14–16 As DEVD is also a preferable substrate for
active caspase-8, any DEVD activity also indirectly reﬂects
the initiator caspase-8 activity, indicating that any caspase
activity without cyt. c release can be scored for possible
direct caspase activation.
17 By employing FRET probe
expressing cell models, we noticed that FRET loss was
initiated only by 12h after PAC-1 treatment in SW480 cells,
which increased rapidly at further time points (Figure 2b and
Supplementary Video S4). DEVD and caspase-3 cleavage
was substantiated by immunoblot that were detected only at
12h upon PAC-1 treatment (Figure 2b). Surprisingly, there
was signiﬁcant DEVD cleavage even in the absence of
caspase-3 (MCF7), which was initiated around 12h upon
PAC-1 treatment, and reconstitution of caspase-3 (MCFC3)
could not induce remarkable difference in the initiation time of
DEVD cleavage (Figures 2c and d; Supplementary Videos
S5a, b and S6). However, cells died rapidly after FRET loss
in case of MCFC3 cells as reﬂected from the loss of cells in
imaging area (Figure 2d). The same results were also
obtained for DEVD cleavage in western blot (Figures 2c and d).
The comparison of temporal data of cyt. c release from the
previous experiments and live cell caspase activation
readouts indirectly suggested that there is no detectable
caspase activation before cyt. c release in any of the cells.
Furthermore, cyt. c-EGFP-overexpressing cells were
incubated with intracellular caspase substrate CaspaTag
sulforhodamine (caspase-3,7) after treating with PAC-1 and
as expected, many cells were observed without caspase
activity even after signiﬁcant release of cyt. c (Supplementary
Figure S3a, upper two panels). Thus, it is clear that PAC-1
induced cyt. c release before caspase activation in all these
cell lines.
Overall, although carried out as independent experimental
systems, our results show that correlating the two critical
events of apoptosis, cyt. c release and caspase activation as
analyzed in real time, can differentiate direct caspase
activation from classical apoptosis where cyt. c release
remains as an initiator for caspase activity. The results show
that cyt. c release is clearly an event upstream to caspase
activation in PAC-1-mediated cell death and is independent of
caspase-3.
Comparative study of cell death in the presence and
absence of procaspase-3. Caspase-3 dependency of
PAC-1-induced cell death was supported by the data of cell
death in multiple normal and cancer cell lines that strongly
placed caspase-3 expression as a deciding factor for its
cytotoxicity.
7.So, in order to further validate the caspase-3
dependency, we compared cell death in the presence
(MCFC3) and absence of caspase-3 (MCF7). Surprisingly,
PAC-1 induced chromatin condensation even in MCF7 cells
after 24h and almost 60% cells showed condensed nuclei
after 48h of treatment although it was earlier and more in
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Cell Death and DiseaseFigure1 Cell-basedmodeltostudykineticsofcyt.crelease.(a)SW480cyt.c-EGFP-expressingcellsweretreatedwithPAC-1andafter3h,time-lapseimagingwasdonebylive-cell
ﬂuorescentmicroscopyattimeintervalsof30min.Therepresentativeimagesareshown(scalebar:10mm.SW480cellsweretreatedbyPAC-1forindicatedtimepointsandcyt.crelease
was checked by immunoblot in cytosolic fraction after digitonin permeabilization. (b) Caspase-3 lacking MCF7 cells werestably transfected with cyt. c-EGFP andtreatedwith PAC-1after
staining with Hoechst. Live cell time-lapse imaging was done by ﬂuorescent microscopy with a time interval of 15min. Representative images of indicated time points are shown (scale
bars:10mm).Diffusepatternindicatedthecyt.creleasefrommitochondriatocytosol,whichisinitiatedaround8hbutnucleuswasnotcondensedevenupto16h.Thecyt.creleasewas
also checked by western blot in cytosolic fraction of PAC-1 treated MCF7 cells after digitonin permeabilization. (c) Caspase-3-expressing MCFC3 cells were stably transfected with cyt. c-
EGFPandtreatedwithPAC-1afterHoechststaining.Time-lapseimagingwasdoneattimeintervalsof20min.Representativeimagesareshown(scalebars:10mm)andtheresultswere
also substantiated by western blot in MCF C3 cells after drug treatment as earlier. The fragmentation of cells after cyt. c release is rapid in caspase-3-expressing cells compared with
MCF7. The arrows represent the condensed nucleus after cyt. c release. But, the initiation of cyt. c release was almost at same time point in both the cells (around 8–9h)
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Cell Death and DiseaseMCFC3 cells (Figure 3a). Long-term clonogenic survival
(Figure 3b), also suggested that PAC-1 can target MCF7
cells. In both the experiments, MCFC3 cells were more
sensitized to PAC-1 as has been already reported for several
drugs. Quite interestingly, we noticed that mitochondrial
membrane potential (Dcm) loss was initiated early in both the
cells at 8h after treatment, and it was more pronounced at
later time points indicating a prominent role of mitochondria
in the apoptosis induced by PAC-1 (Figure 3c). Cleavage of
caspase-3 in MCFC3 cells was evident by 12h after PAC-1
treatment in western blot, again validating our previous FRET
probe readouts. Activation of other caspases like caspase-7,
8, 2, 9 as well as PARP-1 cleavage was also more in MCFC3
cells than MCF7 cells (Figure 3d). Caspase inhibitors failed
to alter the release of cyt. c in MCF7 cells indicating that its
release is independent of any undetectable caspase activity
(Supplementary Figure S3b). Furthermore, Dcm loss is an
early event, which is initiated even in the absence of
caspase-3, suggesting the role of mitochondria-mediated
apoptosis by PAC-1. The results suggest that PAC-1 can
induce caspase activation in both MCF7 and MCFC3 cells,
and the presence of caspase-3 probably augments the cell
death by feedback mechanism.
Dwm loss preceded cyt. c release and caspase activa-
tion. As there is no consensus regarding the kinetics of Dcm
loss and cyt. c release, we analyzed both the events in a
kinetic mode after staining MCFC3 and MCF7cells with
tetramethyl-rhodamine methyl ester (TMRM).
18,19 The kinetic
study demonstrated that Dcm loss preceded cyt. c release
after PAC-1 treatment both in the presence and absence of
caspase-3 (Supplementary Video S7, Figure 4a, and Supple-
mentary Figure S3c).
Despite extensive studies, the key upstream events critical
for the release of cyt. c in drug-induced apoptosis still remains
elusive.
19 Bax conformational activation and its translocation
to the mitochondria are some of the early changes that
contribute to cyt. c release.
3 Analysis of Dcm loss and Bax
mitochondrial translocation employing MCF7 Bax-EGFP cells
bylive-cell imagingshowedlossofTMRMintensityjust before
Bax translocation in PAC-1-induced apoptosis, indicating that
the signaling proceeds in sequence of Dcm loss – Bax
translocation – cyt. c release and DEVD activity (Supplemen-
tary Figure S4a). Also, time-lapse imaging of MCF7 Bid-
DsRed-expressingcellstreatedwithPAC-1failedtoshowany
indication of Bid translocation (Supplementary Figure S4b).
In general, the role of mitochondria in the initiation process
of apoptosis can be conclusively ascertained from the above
sequence of early events of apoptosis and caspase activation
determinedusinglivecell-basedtoolsasdescribed.However,
to get meaningful quantitative information, readout from a
large population of cells for both Dcm loss and caspase
activation is essential for large compound library screening.
So, we have adapted the FRET probe expressing cells for
simultaneous analysis of FRET ratio and Dcm loss by high-
throughput imaging in FRET probe expressing SiHa and
MCF7 cells(SupplementaryFigure S5a).If thereisFRET loss
without Dcm loss, mitochondria-independent caspase activa-
tion can be scored. The scatter plot demonstrated that TMRM
intensity is signiﬁcantly reduced in all cells that showed FRET
ratio change from the control (Figures 4b and c). We did not
observe any cell with FRET loss without Dcm loss upon
treatment with PAC-1. The results point that Dcm loss
occurred before caspase activation. The data were also
substantiated by live-cell imaging of FRET probe expressing
MCF7 and MCFC3 cells in real time manner stained with
TMRM before PAC-1 treatment (Supplementary Figure S5b,
lower two panels). Overall, the study substantiated the
importance of these cellular models to ﬁsh out direct caspase
activators and also indicated that PAC-1 induces Dcm loss
followed by cyt. c release, which subsequently triggers
downstream caspase-3 activation like any other classical
apoptosis inducing drug.
Bcl-2 and Bcl-xL overexpression slightly reduced cyt. c
release, delayed caspase activation and cell death. The
most promising feature of direct activation of caspases in
cancers is its possible ability to be killed cells with acquired
drug resistance due to loss of proapoptotic proteins like Bax
or Bak, and overexpression of antiapoptotic proteins like Bcl-2
and Bcl-xL.
4,20–22. Such cells are common in most solid
tumors and are difﬁcult to be killed by conventional antitumor
agents that promote cell death through cyt. c-dependent
caspase activation. Therefore, to know the role of Bcl-2 and
Bcl-xL in PAC-1-mediated cell death, we stably generated
MCFC3 cells with Bcl-2-EGFP and Bcl-xL-GFP plasmids
(Supplementary Figure S6a). After conﬁrmation of its drug-
resistant property (Supplementary Figure S6b), cell death
was evaluated in these cells by examining nuclear
condensation (Figure 5a), Dcm loss by TMRM staining
(Figure 5c) and cell survival by clonogenicity assay
(Figure 5b) after treatment with PAC-1. Compared with
anticancer drugs like cis-platin, staurosporine and etoposide,
PAC-1 could kill Bcl-2 and Bcl-xL-overexpressing cells in a
delayed manner. PAC-1 was able to eliminate Bcl-2 and
Bcl-xL-overexpressing cells efﬁciently although cell rescue
was comparatively higher than MCFC3 cells as observed
from the clonogenicity assay.
Figure 2 Cell-based model to track down caspase activation in kinetic mode. (a) The schematic representation of FRET probe ECFP-DEVD-EYFP used for monitoring
caspase activation. (b) SW480 cells stably expressing FRET probe were treated with PAC-1(100mM) and ratio imaging was carried out as described with a time interval of
15min after3hof drugaddition.Therepresentative imagesforCFPchannel,FRET-YFPchannelandmergedimagesat indicatedtimepointsare shown(scalebar:100mm).
Loss of FRET upon caspase activation is reﬂected in enhanced blue emission with reduction in FRET YFP emission. The change of color from green to blue in the merged
channelsmarksthecellswithcaspaseactivation.ThepercentageofcellswithFRETloss(bluecellsinmergedimages)wasscoredandrepresentedasgraph.Thecleavageof
FRET probe by active caspases was detected by western blot. The appearance of cleaved band of CFP and YFP suggest that DEVD cleavage is initiated at 12h. Blot was
reprobed with Caspase-3 antibody to show the presence of active caspase-3. b- actin served as loading control (c and d). Similarly, time-lapse imaging carried out for MCF7
and MCFC3 FRET probe expressing cells and FRET loss cells were scored and represented in graph. DEVD cleavage was also detected by immunoblot. In both the cells,
FRET loss initiated by around 12h after PAC-1 treatment (scale bar: 100mm)
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Cell Death and DiseaseFigure 4 Mitochondrial membrane potential loss precedes cyt. c release and caspase activation. (a) MCFC3 cells expressing cyt. c-EGFP were stained with TMRM, and
2hafterdrugtreatmentimagedforbothTMRMandEGFPasdescribed.Therepresentativeimagesareshown(scalebar:10mm).TheTMRMintensityisreducedbeforecyt.c
release. Also, the pixel intensity proﬁle of TMRM (red line) and cyt. c- EGFP (green line) of the indicated cell is shown. This graph and image clearly indicate that (Dcm) loss
preceded cyt. c release from mitochondria. (b) SiHa FRET DEVD probe-expressing cells were seeded in 96-well glass-bottomplate and stained with TMRM before treatment
with drugs. Drugswere addedin mediumcontaininglow concentration of TMRM andimages werecapturedwith montage(2x2) at differenttimepointsusing BDpathway435
imager to read out large number of cell population. Scatter plot of FRET ratio and TMRM intensity after treatment with PAC-1 are shown. The shifting of population to left side
suggests the loss in Dcm. Arrow marks represent the cells with FRET loss as well as Dcm loss. There was no cell detected with FRET loss without Dcm loss. (c) MCF7 cells
expressing FRET DEVD probe were also used for determining FRET loss and TMRM intensity by BD pathway imager as described above. The arrow marks represent the
FRET lost cell populations, which also reﬂected Dcm loss
Figure 3 Induction of cell death in presence and absence of caspase-3 by PAC-1. (a) MCF7 (caspase-3-deﬁcient) and MCFC3 (caspase-3-expressing) cells were stained with
Hoechst 33342 after PAC-1 (75mM) treatment with different time points. The representative images of Hoechst stained nuclei are shown and percentage of condensed nuclei are
represented graphically (n¼4, mean ±S.D.). MCF7 versus MCFC3, 24h treatment (Po0.0015) and 48h treatment (Po0.0003). (b) Clonogenic survival was assessed after PAC-1
treatment in both these cells and the representative images are shown. The clonogenicity was quantiﬁed by reading absorbance after staining with crystal violet as described. The graph
represents clonogenic efﬁciency. (n¼3, mean ±S.D.). PAC-1treatedMCF7versusMCFC3 (Po0.0001). (c) MCF7 and MCFC3 cells were stained with TMRM after PAC-1 treatment
and intensity was analyzed by Flow cytometry (20000 events) to detect the Dcm loss in a time-dependent manner. Shifting of population to the left compared with that of the untreated
populationsuggestslossinDcm.(d)Caspaseactivation(caspase-3,-8,-2,-7,-9)andPARPcleavagewereanalyzedbywesternblotinboththecellsafter PAC-1treatmentwithvarious
time points
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Cell Death and DiseaseFigure 5 Continue.
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Cell Death and DiseaseFigure 5 Induction of mitochondrial cyt. c release, caspase activation and cell death in Bcl-2 and Bcl-xL-overexpressing cells. (a) MCFC3 vector control and Bcl-2 GFP,
Bcl-xLGFP-overexpressingcells weretreatedwith PAC-1(75mM) atindicatedtimepointsandstainedwith Hoechstto analyzenuclearcondensation.Representativeimages
are shown. The percentage of condensed nuclei relative with untreated cells are represented in graph (n¼3, mean ±S.D.). MCFC3 versus MCFC3Bcl-2-GFP cells, and
MCFC3 versus MCFC3Bcl-xL-GFP cells (Po0.001) for both 24h and 36h treatment. (b) Clonogenic survival was assessed in these cells after PAC-1 treatment. The
representative images are shown. The quantitative data of clonogenic efﬁciency determined as described are shown. MCFC3 versus MCFC3Bcl-2-GFP cells, and MCFC3
versus MCFC3Bcl-xL-GFP cells (Po0.001). (c) Flow cytometry data showing Dcm loss in above panel of cell lines after PAC-1 treatment with indicated time points. The
TMRM intensity shifting towards lefts side indicates (Dcm) loss. (d) Caspase activation was detected by western blot in these cells upon PAC-1 treatment with different time
points. (e) MCFC3 vector cells were treated with PAC-1 (75mM) for 12h and 24h, and immunoﬂuorescence was done for checking cyt. c release using ﬂuorescent
microscopy.Representativecyt.cchannel(red),nucleusstainedwithHoechst(blue)andmergedimagesareshown(scalebar:10mm).Thecyt.cimmunoﬂuorescentimages
ofMCFC3Bcl2-GFP-overexpressingcells,andMCFC3Bcl-xLGFP-overexpressingcellsaftertreatmentwiththesamedrugarealsoshown.Thepercentageofcyt.creleasing
cells observed in each group were counted from above experiments and shown as graph (n¼3, mean ±S.D.). MCFC3 versus MCFC3Bcl-2-GFP cells and MCFC3 versus
MCFC3Bcl-xL-GFP cells (Po0.001) for 12h and (Po0.005) for 24h treatment. Cyt. c release was checked by western blot in cytosolic fraction of MCFC3 vector, MCFC3 Bcl-2
GFP and MCFC3 Bcl-xL GFP-overexpressing cells after treatment with PAC-1 with different time points
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Cell Death and DiseaseFurthermore, Bcl-2 and Bcl-xL overexpression could not
prevent caspase-3, 7, 2 and 8 activation, although it was
delayed (Figure 5d). Also, there was only slight reduction and
delay in cyt. c release in Bcl-xL and Bcl-2-overexpressing cells
asshownbyimmunoblotandimmunoﬂuoroscence(Figure5e).
These results clearly indicated that PAC-1 can induce cyt. c
release, subsequent caspase activation and thereby cell death
by bypassing Bcl-2 and Bcl-xL inhibitory function.
Effective cell death in Bak and Bax-deﬁcient mouse
embryonic ﬁbroblasts. Theoretically, if direct caspase
activation in cancer cells is possible by small molecules;
they are likely to generate active caspases in the cells
downstream of Bax/Bak dependent cyt. c release. A recently
reported direct caspase activator 1541 has been shown to
induce cell death in multidrug-resistant mouse embryonic
ﬁbroblasts (MEFs) deﬁcient for both Bax and Bak.
6 However,
previously several classes of compounds have also been
reported to induce cell death in Bax and Bak-deﬁcient cells
by a mitochondria-dependent or -independent manner.
23,24
This necessitates precise deﬁnition of apoptosis signaling in
this model system to ascertain mitochondria-dependent or -
independent cell death induction by such compounds. As
PAC-1 was able to bypass Bcl-2- and Bcl-xL-mediated
mitochondrial protection, we were interested to know if it can
induce death in Bax/Bak double-knockout (DKO) cells
(Figure 6a) with the same efﬁcacy as its wild-type
counterpart. Nuclear condensation, annexin staining and
clonogenicity assay indicated clearly that PAC-1 induces
signiﬁcant cell death in DKO cells but in a delayed manner
than WT cells (Figures 6b–d). Furthermore, analysis of
caspase activation (Figure 6f) and DEVD cleavage
(Figure 6e) by immunoblot and ﬂow cytometry using
intracellular caspase substrate (Supplementary Figure S6c)
suggested that PAC-1 induces caspase-3, 7, 9 and 2
activation in DKO cells, although in a delayed manner than
its WT counterpart.
Mostly Bax and Bak deﬁciency culminates in the failure of
cyt. c release upon apoptotic stimulus. However, there are
alternative mechanisms of cyt. c release independent of Bax
and Bak proteins, but the molecular mechanism is still
elusive.
19 Therefore, we assessed cyt. c release by immuno-
blotting (Figure 6g) and immunoﬂuorescence as well as cyt.
c-EGFP-expressing DKO cells (Figure 6h and supplementary
Figure S6c, bottom panel). We detected release of cyt. c in
DKO cells at 12h, which was signiﬁcantly enhanced around
24h after PAC-1 treatment, however, the release was early
and rapid in wild-type cells. Cyt. c-EGFP release was also
evident from 12h onwards in DKO cells that is consistent with
immunoﬂuorescence (data not shown). These results demon-
strate the ability of PAC-1 to release cyt. c independent of Bax
and Bak by an alternative mechanism leading to subsequent
caspase-3 activation.
Essential role of Apaf-1 for caspase-3 activation. Re-
leased cyt. c forms a complex with Apaf-1 and procaspase-9
known as apoptosome, which causes procaspase-9
activation and subsequent caspase-3 activation.
2 To
conﬁrm that cyt. c release and apoptosome formation is
essential for caspase activation, we employed Apaf-1 knock-
out MEF cells (Figure 7a) as a model system. Nuclear
condensation suggested that Apaf-1 KO cells were highly
resistant to PAC-1 than its WT counterpart (Figure 7b). There
was no caspase-3 activation in MEF Apaf-1 KO cells while
signiﬁcant cleavage was noticed in WT cells (Figure 7c).
Interestingly, we noticed cyt. c release in Apaf-1 KO cells
without any signiﬁcant nuclear condensation up to 24h
(Figure 7d). These results indicate that PAC-1 induces Bax/
Bak-independent cyt. c release and apoptosome formation,
which results into subsequent activation of caspase-3 in Apaf-
1 dependent manner. Overall our studies substantiate that
mitochondrial cyt. c is critical and essential for the caspase
activation in cell system by the ﬁrst direct caspase activator,
identiﬁed in a cell-free system of caspase activation screen.
Discussion
Therapeutic beneﬁt of targeting drug-resistant cancer cells by
direct caspase activation can be achieved only if the
compound can generate active caspases within the cell
without the engagement of upstream mitochondrial
events.
18,25 So,compoundsidentiﬁed usingcell-freesystems
of caspase activation needs to be validated for this activity
using precise cellular models considering the enormous
potential of similar compounds in addressing clinical drug
resistance as well as in understanding the fundamentals of
apoptosis signaling. Current understanding of apoptosis
signaling indicates that if direct caspase activation is possible,
it should generate detectable caspase activity well before the
release of cyt. c from mitochondria. However, it is extremely
difﬁcult to characterize this property in cellular models,
primarily, because of the narrow time window between cyt. c
release and caspase activation, and lack of sensitive cell-
based assays to identify and distinguish direct caspase
Figure 6 Induction of Bax and Bak-independent cyt. c release, caspase activation and cell death by PAC-1. (a) The expression status of Bax and Bak protein in MEF WT
and DKO cells analyzed by western blot. (b) Analysis of nuclear condensation after PAC-1(50mM) treatment in MEF WT and DKO cells by Hoechst staining. Representative
images and graph are shown (n¼4, mean ±S.D.). MEF WT versus DKO, 12h (Po0.0001) and 24h (Po0.001). (c) Clonogenic survival was assessed in both cells upon
PAC-1treatmentasdescribed.Representativegraphandimagesareshown(n¼3,mean±S.D.).MEFWTversusDKO(Po0.001).(d)AnalysisofannexinV–PEstaining
in MEF WT and DKO cells by ﬂow cytometry after treatment with PAC-1. Shifting of population towards right suggests the annexin exposure to cell surface.( e) MEF WT and
DKO cells are transiently transfected with CFP-DEVD-YFP FRET probe and treated with PAC-1 for indicated time points. DEVD cleavage was detected by western blot after
PAC-1 treatment by probing with GFP antibody. (f) Caspase activation was analyzed in MEFs cell by western blot upon PAC-1 treatment for different time points. Caspase-3,
-7,-9,-2,-8andBid-speciﬁcantibodieswereused.HSC-70orb-actinservedasloadingcontrol.(g)Cyt.creleasewasanalyzedincytosolicfractionofdigitoninpermeabilized
MEFs cells by western blot after PAC-1(50mM) treatment in time-dependent manner. (h) MEF DKO cells were transiently transfected with cyt. c-EGFP plasmid and imaged
under ﬂuorescent microscope after PAC-1 treatment for 24h (scale bar: 20mm). The diffuse pattern of cyt. c-EGFP in treated cells indicates its release from mitochondria to
cytosol while granular pattern in untreated cells indicates its mitochondrial location
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10,26,27 We have generated certain
cell-based tools using caspase-speciﬁc FRET probe and
EGFP-fused cyt. c, to identify compounds that can induce
caspase activation well before cyt. c release. Closer analysis
of the results of cyt. c release and caspase activation in real
time by employing these cell-based tools indicate that cyt. c
release preceded caspase activation upon small molecule
PAC-1 treatment similar to other drugs. Quite interest-
ingly, PAC-1 initiated cyt. c release at the same time point
in both caspase-3-expressing and -deﬁcient MCF7 cells.
Intracellular caspase-3, 7 substrate and cell-death analysis
again clariﬁed that caspase activation is a later event when
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PAC-1 can induce apoptosis even in caspase-3-deﬁcient
MCF7 cell although it was delayed than caspase-3-expressing
MCF7 cell.
28 It is well known that MCF7 cell is relatively
insensitive to many cancer chemotherapy drugs and
reconstitution of caspase-3 sensitizes MCF7 cells to drug-
induced apoptosis.
29
The time between cyt. c release and caspase activation
varies signiﬁcantly between cells in response to multiple
drugs,includingﬁrstprocaspase-3activatingcompound1and2.
SW480 cells presented with a wider time gap suggesting
possible post cyt. c negative regulators of caspase-3 in this
cell. Similarly, caspase-3-deﬁcient breast cancer cell MCF7
also showed marked time delay between cyt. c release and
Figure7 AbsenceofApaf-1preventedcelldeathandcaspase-3activation.(a)ConﬁrmationofApaf-1knock-outcellanditswild-typecounterpartbyanalyzingexpression
statusofApaf-1bywesternblot.Apaf-1proteinwasabsentinknockoutcellsasshowninblot.(b)ThecelldeathwasassessedbynuclearcondensationusingHoechststaining
in MEF WT and MEF Apaf-1KO cells after PAC-1(50mM) treatment. The condensed nuclei were counted and percentage has been plotted graphically relative to its control.
Representative images and graph are shown. There was no sign of cell death in MEF Apaf-1KO cells while MEF WT cells were completely dead (n¼4, mean ±S.D.;
Po0.0001). (c) Caspase-3 cleavage was checked in both the cells after PAC-1 treatment by western blot. Caspase-3 cleavage was absent in Apaf-1 KO cell while wild-type
cells showed the 17kDa band of cleaved caspase-3 clearly. (d) The cyt. c release was checked by immunoﬂuorescence in MEF WT and Apaf-1 KO cells. Cyt. c release and
nuclear condensation were massive in WT cells, but in Apaf-1 KO cells nuclear condensation was absent even though cyt. c released was noticed slightly after treatment for
24h (scale bar: 20mm)
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models to characterize cyt. c-independent caspase activation
with the image-based platforms.
Previously evidence of late Dcm loss after caspase
activation carried out by independent cell population-based
experiments was used for indirect measure of direct caspase
activation.
7Incontrast,ourtime-lapseimaging,ﬂowcytometric
analysisandhigh-throughputimagingdataindicatethatPAC-1
induces Dcm loss before cyt. c release, Bax translocation and
caspase activation. Interestingly, PAC-1 could not induce cell
death and caspase-3 activation in the absence of Apaf-1,
suggesting that apoptosome formation is essential for
caspase-3 activation by PAC-1-mediated cell death. This
observation and failure to reduce cyt. c release in caspase
inhibitor-treated cells, rules out the role of any undetectable
residual caspase activity on cyt. c release by feedback. Even
though PAC-1 did not activate caspase-3 directly, our results
reveal that Bcl-2 and Bcl-xL-overexpressing cells were also
killed by PAC-1 through cyt. c release and caspase activation.
Moreover, PAC-1 can also induce Bax and Bak-independent
cyt. c release and caspase activation although currently the
mechanismbehind this, is notclear. Theprobable role of other
initiator caspases like caspase-8 is indirectly ruled out by
utilizing Apaf-1 KO cells in which we failed to ﬁnd caspase-3
activation and cell death. We also failed to observe any Bid
translocation by live-cell imaging of MCF7 Bid-DsRed-expres-
sing cells, which again ruled out the role of caspase-8.
We deﬁne for the ﬁrst time, cell-based tools to identify non-
classical apoptosis inducers with direct caspase-activating
potential without any ambiguity. The results also indicate that
the most important key molecular events expected from such
compounds like detection of activated caspases earlier to
cyt. c release and apoptosome formation should be thor-
oughlyestablishedinkineticmodeinvalidatingdirectcaspase
activators. Given the clinical potential of direct caspase
activators, it is essential to screen large compound libraries
for identifying positive hits using such deﬁned cellular models.
As the model systems described here are adaptable for
high-throughput screening, it is expected to accelerate the
discovery of novel direct caspase activators in cellular
systems to address clinical drug resistance.
Materials and Methods
Cell culture maintenance and treatment. Breast cancer cell line MCF7
(NCI, Bethesda, MD, USA), colon cancer cell line SW480 and cervical cancer cell
line SiHa (ATCC, Manassas, VA, USA) were maintained in Dulbecco’s Modiﬁed
Eagle’s medium containing 10% FBS in a humidiﬁed CO2 incubator at 371C.
Immortalized murine MEF wild type and respective Bax/Bak knockout (MEF DKO)
were provided by Stanely J. Korsemeyer (Harvard Medical School, Boston, MA,
USA) and MEF Apaf-1 KO cells were provided by Dr Tak W Mak, Ontario Cancer
Institute (Canada). MEFs cells were maintained in DMEM supplemented with 10%
FBS and antibiotics.
PAC-1(Calbiochem, San Diego, CA, USA) was used in the concentration range of
50–100mM according to the cell line. Other drugs like staurosporine (1mM), etoposide
(50mM), trichostatin A (4mM), cis-platin (50mg/ml), camptothecin (5mM), colchicine
(5mg/ml),actinomycinD(10mM)andMG132(10mM) werepurchasedfromSigma(St.
Louis, MO, USA). Caspase inhibitor VI (10mM) was purchased from Calbiochem.
Plasmids and generation of stable cell lines. Full-length mouse cyt. c
cloned in pEGFP-N1 vector was kindly provided by Dr Douglas Green (St. Jude
Children’s Research Hospital, Memphis, TN, USA). SW480, SiHa, MCF7 and MCF
C3 were transfected with this plasmid using lipofectamine 2000 plus (Invitrogen,
Carlsbad,CA,USA)asper themanufacture’s instruction, andselectedin800mg/ml
of G418-containingmediumfor1month.Onlytheclonethatexpressedcyt.c-EGFP
with the correct mitochondrial targeting were further expanded and used for the
study. The correct mitochondrial localization was veriﬁed by staining the cells with
Mitotracker deep Red (Invitrogen) or reexpressing with MitoDsRed (Clontech,
Mountain View, CA, USA).
Caspase-3 speciﬁc FRET probe pcDNA 3 DEVD (ECFP-DEVD-EYFP) plasmid
was kindly provided by Dr Gavin Welsh (University of Bristol, UK). Cells were
transfected with Lipofectamine using a standard protocol. After sorting by FACS,
cells were maintained in G418-containing medium. Many clones were selected,
expanded and studied for functional competence by FRET imaging after treating
with standard anticancer drugs. The best clone with optimum FRET value for
imaging was selected for the study.
The expression vectors pCDNA3 Bcl2- EGFP, Bcl-xL-EGFP and Bax EGFP,
provided by Dr Clark Distelhorst were transfected in MCFC3 cells using
lipofectamine and maintained in G418 selection medium. Bid DsRed (Clontech)
was transfected in MCF7 cells to generate stable clones as described above. The
plasmid pCDNA3 caspase-3 was provided by Dr VM Dixit (Genentech, USA) and
transfected in MCF7 cells as described, and positive clones were selected by
maintaining in G418.
Live-cell imaging. Cells were grown on chambered cover glass (Lab-Tek,
Nunc, Rochester, NY, USA), to which the indicated drugs reconstituted in DMEM
containing 5% FBS was added. For imaging, cells were stained as described and imaged
in a live-cell incubation chamber (Tokai Hit, Shizuoka-ken, Japan) that maintains optimum
CO2, temperature and humidity. Imaging was carried out using a  20 Plan Apo 1 NA
objective under an inverted ﬂuorescence microscope (Nikon Eclipse, TE2000-E, Tokyo,
Japan)equippedwithaCARVIIconfocalimager(BectonDickinson(BD)MountView,CA,
USA) and an automated excitation and emission ﬁlter wheel. The images were captured
using EMCCD camera Andor iXON 885 using IPLab software (BD) at regular intervals for
the indicated time periods. To minimize photobleaching, the intensity of the light was
reduced to 1% by intensity iris control.
For live-cell imagingof cyt. c, the cells were grown on chambered cover glass as
describedearlierandtreatedwithdrugs.Afterdrugtreatment,thecellswereimaged
using TE2000 E ﬂuorescent microscope using Retiga Exi (Q. Imaging, Surrey, BC,
Canada) camera at regular intervals using NIS Element software. For live-cell
imaging of TMRM and cyt. c-EGFP or Bax, the respective cells were stained with
100nM of TMRM (Molecular Probes, #T-668, Eugene, OR, USA) followed by
imaging in drug and 20nM of TMRM containing medium. For ratio imaging of CFP-
YFP FRET, CFP was excited with 438±12nm band pass ﬁlter, and dual emission
was collected at 480±15nm band pass ﬁlter for CFP channel and EYFP-FRET
channel with 542±27nm band pass ﬁlter.
Immunoblotting. After treatment with drugs, cells were lysed in lysis buffer
containing 1% NP-40 and protease inhibitor cocktail by incubating in ice for 30min.
Proteins were estimated by using Bradford reagent and 40mg of proteins were
resolved electrophoretically on 8–15% SDS polyacrylamide gels, transferred to
nitrocellulose membranes and detected by chemiluminescence (Amersham,
Buckinghamshire, UK) or by Diamino benzedine (Sigma).
For analyzing cyt. c release from mitochondria, cells were permeabilized
with digitonin containing cytosolic extraction buffer with different concentration
(40–150mg/ml) depending on the cell, and supernatant(free of mitochondria) was
obtained by centrifugation at 15000r.p.m. for 30min and then again 15000r.p.m.
for 5min. Cytosolic fraction (supernatant) was resolved on 15% SDS-PAGE gel.
The following primary antibodies were used for immunoblotting and immuno-
ﬂuorescence: Caspase 3 (9662), cleaved caspase 3 (9661), caspase 9 (9502),
cleaved caspase 9 (9505), mouse-speciﬁc caspase 9 (9504), mouse-
speciﬁc cleaved caspase 9 (9509), caspase 8 (9746), mouse-speciﬁc caspase 8
(4927), cleaved caspase 7 (9491), PARP (9542), BID (2002), caspase 2 (C2; 2224)
and GFP (2555) were purchased from Cell Signaling Technology (Beverly, MA,
USA). Apaf1(sc-8339), HSC70(7298), b-Actin (sc-1616), cyt. c (7H8): (sc-13560),
Bax(7480), Bak(832), Bcl-2 sc-7382 and Bcl-XL(sc-7195) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Caspase 2 (clone 10C6) from
Chemicon (Temecula, CA, USA). Cyt. c (6H2.B4) from BD Bioscience (San Diego,
CA, USA) was used for the study.
Immunoﬂuorescence. Cells were seeded in 96-well glass-bottom plates
(Whatman, Clifton, NJ, USA) and ﬁxed with ice-cold acetone:methanol (1:1) for
10min.Afterblockingwith3%BSA,cellswereincubatedwithanti-cyt.c(6H2.B4)at
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(Molecular Probes). After 1h incubation, cells were washed with PBS and imaged
using ﬂuorescent microscope TE 2000E using speciﬁc ﬁlter combinations.
High-throughput Imaging. Cells were seeded in a 96-well glass-bottom
plate(BD)andafter48h,stainedwithTMRM(50nM)andthentreatedwithdifferent
drugs along with low concentration of TMRM (20nM). Images were captured using
BD Pathway Bioimager 435 with different time points by setting 3x3 montage and
speciﬁc Macro using AttoVision software. Both TMRM intensity and FRET ratio
intensity for caspase-3, 7 speciﬁc FRET probe were analyzed after proper
segmentation from scatter plot. For imaging of CFP-DEVD-YFP, the Pathway
BioimagerwasconﬁguredwithECFPEx:438±12nmbandpassﬁlterDichroic:458
LP and dual emission at 483þ15nm for CFP, 542±27nm for EYFP FRET was
collected by automated ﬁlter wheel combinations in ratio mode acquisition.
Analysis of chromatin condensation. After treatment with drugs, the
cells were stained with Hoechst 33342 stain (1mg/ml) and incubated for 10min at
371C and images were taken under UV ﬁlter using Epi-ﬂuorescent Microscope
(Nikon TE 2000E). Condensed nucleus was counted against total number of
nucleus in the ﬁeld, and the percentage of apoptotic nuclei were calculated and
plotted graphically.
Flow cytometry analyses. Loss of Dcm was measured by using the
ﬂuorescent dye TMRM. After treatment with drugs, cells were trypsinized and
centrifugedat3000r.p.m.for5minandonceagainwashedwithOPTIMEMmedium.
Cells were then incubated for 10min at 371C after adding OPTIMEM medium
containing TMRM dye (molecular probes) with 50nM and analyzed by FACS Aria1
(Becton Dickinson).
Apoptotic cells were quantiﬁed on a single cell basis by FACS using PE
conjugated Annexin V (BD PharMingen, San Diego, CA, USA). After treatment,
cells were harvested by trypsinization and washed with 1  annexin binding buffer
andthenstainedwithPEconjugatedannexinV(redﬂuorescence)andincubatedfor
30minat371C.Total20000cellswereevaluatedforannexinbindingbyFACSAria.
Intracellular caspases activity was detected by using caspases detection kit from
Calbiochem and Chemicon International. Red-LEHD-FMK (caspase 9), Red-IETD-
FMK(caspase 8), caspase 2 ﬂuorescein and CaspaTag sulforhodamine (caspase 3, 7)
substrates were used as per the kit protocol for staining the cells and analyzing by FACS.
Clonogenicity assays. The colony-forming potential of adherent cells was
measured as describedpreviously (Janssen et al., 2007). Brieﬂy, cells were seeded
in six-well plates with 50% conﬂuency and treated with PAC1 on the following day.
After 24 or 48h, cells were washed and maintained in normal medium for another
24huntiltheuntreatedcontrolsreachedmorethan90%conﬂuency.Cellsweresplit
and reseeded with 1:100 dilution in new plates. After 5 or 7 days, viable cells were
stainedwith0.5%CrystalVioletandsolubilizedin33%aceticacid.Absorbancewas
measured at 590nm (A590). Relative proliferation was deﬁned as A590 of test well
 100 divided by the A590 of untreated well.
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